Injectable Microbeads for Delivery of Buprenorphine

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 DA09746-01,
Agency Tracking Number: 29312
Amount: $99,999.00
Phase: Phase I
Program: SBIR
Awards Year: 1995
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Bend Research, Inc.
64550 Research Road, Bend, OR, 97701
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 James Nightingale
 () -
Business Contact
Phone: () -
Research Institution
The objective of this research program is to demonstrate the feasibility of a new controlled-releasuse in an injectable formulation of buprenorphine to improve treatment of opioid dependence. The keytechnology is the use of bioerodible microporous microbeads with a controllable structure that allowas well as easily varied release rates and durations of release. These controlled-release microbeadsinjectable formulation that would result in much-improved patient compliance, better efficacy, and fthe case with current therapies. Specific tasks in Phase l include identification of bioerodible polcandidate microporous microbeads, in vitro testing of drug- loaded microbeads, determination of shorvivo evaluation of candidate microbeads in rhesus monkeys. The feasibility of this approach will bevitro and in vivo tests indicate efficacy over 3- to 14-day time periods. If this is the case, a Phaon further development of this technology and completion of preclinical studies necessary for submisInvestigational New Drug application.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government